TRex Bio Prices $117M IPO to Support Immune Drug Work

TRex Bio IPO raises $116.7 million, prices at bottom of range

The clinical-stage biotech sold about 8.3 million shares at $14 each, the low end of its $14-to-$16 marketed range

Eli Lilly-backed TRexBio prices $117M US IPO at $14 per share (LLY:NYSE)

TRex Bio (TRXB) prices its IPO at $14, raising ~$116.7M ahead of its Nasdaq debut Oct. 9.

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension

The appetite for biotech IPOs remains strong, especially when Eli Lilly and Nobel Prize-winning science are involved. TRexBio priced its initial stock sale Thursday, raising $116.7 million in ...

TRex Bio Prices IPO at $14, Targets $117 Million Gross

The clinical-stage biotechnology company is offering 8.33 million shares and expects approximately $116.7 million in gross proceeds.

Eli Lilly-Backed Biotech TRex Raises $116.7 Million in US IPO

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.